Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22104101 | 0.90 | MAPK1 (0.60) | MAPK1MEN1KMT2ATDP1CYP3A4 | |
| SCHEMBL3415585 | 0.74 | MAPK1 (0.48) | MAPK1MEN1KMT2AARALDH1A1 | |
| SCHEMBL14922436 | 0.74 | — | — | |
| SCHEMBL113383 | 0.72 | MAPK1 (0.81) | MAPK1MEN1KMT2A | |
| SCHEMBL20906278 | 0.72 | MAPK1 (0.81) | MAPK1MEN1KMT2A | |
| SCHEMBL12875455 | 0.72 | MAPK1 (0.46) | MAPK1MEN1KMT2AARALDH1A1 | |
| SCHEMBL6018054 | 0.72 | MAPK1 (0.81) | MAPK1MEN1KMT2A | |
| SCHEMBL13931015 | 0.72 | MAPK1 (0.46) | MAPK1MEN1KMT2AARALDH1A1 | |
| SCHEMBL12310819 | 0.72 | MAPK1 (0.46) | MAPK1MEN1KMT2AARALDH1A1 | |
| SCHEMBL13621479 | 0.72 | MAPK1 (0.46) | MAPK1MEN1KMT2ATDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11573488-B2 | Composition for holographic recording medium, and holographic recording medium | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-02-07 | — | — | US | disclosed |
| US-10221208-B2 | Methods of producing an HIV maturation inhibitor | ViiV Healthcare UK (No.4) Limited (GB) | 2019-03-05 | — | — | US | disclosed |
| US-10221208-B2 | Methods of producing an HIV maturation inhibitor | ViiV Healthcare UK (No.4) Limited (GB) | 2019-03-05 | — | — | US | disclosed |
| US-20180094019-A1 | CRYSTALLINE FORMS OF MODIFIED TRITERPENOID HYDROCHLORIDE SALTS WITH HIV MATURATION INHIBITOR ACTIVITY | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2018-04-05 | — | — | US | disclosed |
| US-20180094019-A1 | CRYSTALLINE FORMS OF MODIFIED TRITERPENOID HYDROCHLORIDE SALTS WITH HIV MATURATION INHIBITOR ACTIVITY | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2018-04-05 | — | — | US | disclosed |
| US-20180094019-A1 | CRYSTALLINE FORMS OF MODIFIED TRITERPENOID HYDROCHLORIDE SALTS WITH HIV MATURATION INHIBITOR ACTIVITY | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2018-04-05 | — | — | US | disclosed |
| US-20180072691-A1 | METHODS OF PRODUCING AN HIV MATURATION INHIBITOR | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
| EP-3283467-A1 | METHODS OF PRODUCING AN HIV MATURATION INHIBITOR | VIIV Healthcare UK(No.4) Limited (GB) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168462-A1 | CRYSTALLINE FORMS OF MODIFIED TRITERPENOID HYDROCHLORIDE SALTS WITH HIV MATURATION INHIBITOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168447-A1 | METHODS OF PRODUCING AN HIV MATURATION INHIBITOR | VIIV HEALTHCARE (No.4) LIMITED (GB) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221208-B2 | Methods of producing an HIV maturation inhibitor | TMBIM6, MCL1, FURIN | MAPK1 3707/4885MEN1 2058/4885KMT2A 1478/4885 |
| US-20180072691-A1 | METHODS OF PRODUCING AN HIV MATURATION INHIBITOR | TMBIM6, MCL1, FURIN | MAPK1 3707/4885MEN1 2058/4885KMT2A 1478/4885 |
| US-20180094019-A1 | CRYSTALLINE FORMS OF MODIFIED TRITERPENOID HYDROCHLORIDE SALTS WITH HIV MATURATION INHIBITOR ACTIVITY | CYP4F11, GTF3C4, CYP4A11 | MAPK1 1261/4885MEN1 1019/4885KMT2A 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.